Display options
Cite
Wang Q, Li A, Jin J, et al. Targeted interfering DEP domain containing 1 protein induces apoptosis in A549 lung adenocarcinoma cells through the NF-κB signaling pathway. Onco Targets Ther. 2017;10:4443-4454doi: 10.2147/OTT.S142244.
Wang, Q., Li, A., Jin, J., & Huang, G. (2017). Targeted interfering DEP domain containing 1 protein induces apoptosis in A549 lung adenocarcinoma cells through the NF-κB signaling pathway. OncoTargets and therapy, 104443-4454. https://doi.org/10.2147/OTT.S142244
Wang, Qingqing, et al. "Targeted interfering DEP domain containing 1 protein induces apoptosis in A549 lung adenocarcinoma cells through the NF-κB signaling pathway." OncoTargets and therapy vol. 10 (2017): 4443-4454. doi: https://doi.org/10.2147/OTT.S142244
Wang Q, Li A, Jin J, Huang G. Targeted interfering DEP domain containing 1 protein induces apoptosis in A549 lung adenocarcinoma cells through the NF-κB signaling pathway. Onco Targets Ther. 2017 Sep 11;10:4443-4454. doi: 10.2147/OTT.S142244. eCollection 2017. PMID: 28979136; PMCID: PMC5602701.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2017 Sep 11;10:4443-4454. doi: 10.2147/OTT.S142244. eCollection 2017.

Targeted interfering DEP domain containing 1 protein induces apoptosis in A549 lung adenocarcinoma cells through the NF-κB signaling pathway.

OncoTargets and therapy

Qingqing Wang, Aili Li, Junfei Jin, Guojin Huang

Affiliations

  1. Laboratory of Respiratory Disease, Affiliated Hospital of Guilin Medical University.
  2. China-USA Lipids in Health and Disease Research Center, Guilin Medical University.
  3. Laboratory of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.

PMID: 28979136 PMCID: PMC5602701 DOI: 10.2147/OTT.S142244

Abstract

Ectopic expression of DEP domain containing 1 (DEPDC1) in lung adenocarcinomas is associated with poor prognosis, but its role and the underlying mechanism remain unknown. In this study, DEPDC1 expression in lung cancer cell lines was examined with Western blot assay, and DEPDC1-positive cell A549 was selected for further experiments. DEPDC1 inhibitor miR-130a was overexpressed in A549 cells, and the proliferation and apoptosis of these cells were analyzed with cell counting and flow cytometry assay. Interfering peptide 11R-DEP:611-628 and JNK inhibitor SP600125 were used alone or in combination to treat A549 cells, and the cell proliferation and apoptosis were assessed by flow cytometry assay; caspase 3 and cleaved caspase 3, phosphor-JNK, and total JNK were detected by Western blotting; and nuclear factor kappa B (NF-κB) localization was determined by immunofluorescence staining. We found that miR-130a and 11R-DEP:611-628 peptides (5 μM) both inhibited A549 proliferation and induced apoptosis. We observed that 11R-DEP:611-628 peptide treatment resulted in elevated A20 expression, dramatically reduced nuclear NF-κB, and increased phosphor-JNK. These findings indicate that DEPDC1 inhibits apoptosis of A549 cell by suppressing A20 expression to regulate NF-κB activity, and that JNK plays a protective role upon 11R-DEP:611-628 peptide treatment. In conclusion, DEPDC1 might be a novel therapeutic target for lung cancer, and the 11R-DEP:611-628 peptide is a potent apoptosis inducer in A549 cells.

Keywords: A20; A549 cells; DEPDC1; NF-κB; lung cancer; miR-130a

Conflict of interest statement

Disclosure The authors report no conflicts of interests in this work.

References

  1. CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41 - PubMed
  2. Cancer Res. 2010 Jul 15;70(14):5829-39 - PubMed
  3. Asian Pac J Cancer Prev. 2014;15(24):10917-22 - PubMed
  4. Biochim Biophys Acta. 1998 Jun 11;1385(1):157-64 - PubMed
  5. J Biol Chem. 2007 May 11;282(19):14283-90 - PubMed
  6. CA Cancer J Clin. 2017 Jan;67(1):7-30 - PubMed
  7. Nature. 1995 Jul 6;376(6535):37-43 - PubMed
  8. Cancer Lett. 2017 Jan 28;385:150-159 - PubMed
  9. N Engl J Med. 2016 May 12;374(19):1864-73 - PubMed
  10. Oncotarget. 2014 Nov 15;5(21):10271-9 - PubMed
  11. Oncol Rep. 2013 Oct;30(4):1957-64 - PubMed
  12. CA Cancer J Clin. 2015 Mar;65(2):87-108 - PubMed
  13. J Cell Sci. 2006 Jan 1;119(Pt 1):153-61 - PubMed
  14. Mol Cancer. 2011 Feb 11;10(1):15 - PubMed
  15. Nat Cell Biol. 2014 Aug;16(8):812-20 - PubMed
  16. Oncogene. 2007 Sep 27;26(44):6448-55 - PubMed
  17. Trends Biochem Sci. 1996 Jul;21(7):245-6 - PubMed
  18. Cancer Res. 2012 Jan 1;72(1):100-11 - PubMed

Publication Types